ATE443084T1 - Genetisch modifizierte, menschliche, natürliche killerzellenlinien: - Google Patents
Genetisch modifizierte, menschliche, natürliche killerzellenlinien:Info
- Publication number
- ATE443084T1 ATE443084T1 AT05789289T AT05789289T ATE443084T1 AT E443084 T1 ATE443084 T1 AT E443084T1 AT 05789289 T AT05789289 T AT 05789289T AT 05789289 T AT05789289 T AT 05789289T AT E443084 T1 ATE443084 T1 AT E443084T1
- Authority
- AT
- Austria
- Prior art keywords
- natural killer
- killer cell
- cell lines
- genetically modified
- modified
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 108010087819 Fc receptors Proteins 0.000 abstract 2
- 102000009109 Fc receptors Human genes 0.000 abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000034285 signal transducing proteins Human genes 0.000 abstract 1
- 108091006024 signal transducing proteins Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58658104P | 2004-07-10 | 2004-07-10 | |
PCT/US2005/024229 WO2006023148A2 (en) | 2004-07-10 | 2005-07-08 | Genetically modified human natural killer cell lines |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE443084T1 true ATE443084T1 (de) | 2009-10-15 |
Family
ID=35968029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05789289T ATE443084T1 (de) | 2004-07-10 | 2005-07-08 | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
Country Status (12)
Country | Link |
---|---|
US (8) | US7618817B2 (de) |
EP (5) | EP2921500B1 (de) |
AT (1) | ATE443084T1 (de) |
AU (1) | AU2005277831B2 (de) |
CA (2) | CA3052445C (de) |
DE (1) | DE602005016683D1 (de) |
DK (4) | DK2112162T3 (de) |
ES (3) | ES2925912T3 (de) |
HK (2) | HK1203975A1 (de) |
PL (1) | PL2921500T3 (de) |
PT (1) | PT2921500T (de) |
WO (1) | WO2006023148A2 (de) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3052445C (en) | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
WO2006036445A2 (en) | 2004-09-24 | 2006-04-06 | Trustees Of Dartmouth College | Chimeric nk receptor and methods for treating cancer |
WO2008031056A2 (en) | 2006-09-08 | 2008-03-13 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
RU2549701C2 (ru) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний |
WO2009041113A1 (ja) * | 2007-09-28 | 2009-04-02 | Olympus Corporation | Fc受容体遺伝子導入NK細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
RU2490278C2 (ru) | 2007-12-21 | 2013-08-20 | Медиммун Лимитед | ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173 |
EP2161339A1 (de) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC mit modifizierten NK92-Zellen |
BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
CN110511278A (zh) | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
DK3052192T3 (da) | 2013-10-02 | 2020-09-28 | Medimmune Llc | Neutraliserende anti-influenza a-antistoffer og anvendelser deraf |
WO2015066054A1 (en) | 2013-11-01 | 2015-05-07 | Conkwest, Inc. | Tumoricidal and antimicrobial compositions and methods |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
CN113699159A (zh) * | 2014-03-28 | 2021-11-26 | 明尼苏达大学评议会 | 涉及经工程改造的cd16的多肽、细胞和方法 |
CN106459914B (zh) | 2014-05-15 | 2020-11-06 | 新加坡国立大学 | 经修饰的自然杀伤细胞及其用途 |
US20170182292A1 (en) | 2014-05-22 | 2017-06-29 | Nantkwest, Inc. | Treating solid tumours with nk-92 cells applied by microcatheter |
WO2015179833A1 (en) * | 2014-05-23 | 2015-11-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating antibody resistance |
US10550197B2 (en) | 2014-06-18 | 2020-02-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | CAR-expressing NK-92 cells as cell therapeutic agents |
EP3204020B1 (de) * | 2014-10-06 | 2023-01-18 | ImmunityBio, Inc. | Behandlung von viralem hämorrhagischem fieber mit nk-92-zellen |
GB201501175D0 (en) * | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
WO2016160621A2 (en) * | 2015-03-27 | 2016-10-06 | Nantkwest, Inc. | Nk-92 cells in combination therapy with cancer drugs |
IL301331A (en) * | 2015-03-27 | 2023-05-01 | Immunitybio Inc | Genetically modified NK-92 cells and monoclonal antibodies for cancer therapy |
RU2017140778A (ru) | 2015-04-25 | 2019-05-27 | Дзе Дженерал Хоспитал Корпорейшн | Комбинированная терапия антифугетактическим средством и противораковым средством, и композиции для лечения рака |
AU2016271323B2 (en) | 2015-06-01 | 2022-08-25 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
KR20240013282A (ko) | 2015-06-10 | 2024-01-30 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
ES2939084T3 (es) * | 2015-07-29 | 2023-04-18 | Onk Therapeutics Ltd | Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada |
US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
CA2999083A1 (en) | 2015-09-18 | 2017-03-23 | The General Hospital Corporation Dba Massachusetts General Hospital | Localized delivery of anti-fugetactic agent for treatment of cancer |
US10533157B1 (en) | 2015-12-03 | 2020-01-14 | Nantbio, Inc. | Recombinant NK cells expressing co-stimulatory molecules |
WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
WO2017132202A1 (en) * | 2016-01-25 | 2017-08-03 | Nant Holdings Ip, Llc | Nk cells with altered cxcl12/cxcr4 signaling |
WO2017184534A1 (en) * | 2016-04-18 | 2017-10-26 | The Gorlin Companies | Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy |
US20200316118A1 (en) | 2016-05-19 | 2020-10-08 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
WO2018053270A1 (en) * | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Modified natural killer cells for the treatment of cancer |
JP2019532640A (ja) * | 2016-09-29 | 2019-11-14 | ナントクエスト インコーポレイテッド | 免疫原性が低下したhlaクラスi欠損nk−92細胞 |
WO2018129199A1 (en) | 2017-01-04 | 2018-07-12 | Nova Southeastern University | Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof |
JP7118072B2 (ja) | 2017-01-06 | 2022-08-15 | イミュニティーバイオ インコーポレイテッド | Cd96/tigit発現が低下した遺伝子改変型nk-92細胞 |
AU2018214558B2 (en) * | 2017-02-01 | 2020-08-27 | Immunitybio, Inc. | Calreticulin-mediated cancer treatment |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
WO2018148462A1 (en) * | 2017-02-09 | 2018-08-16 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Car t細胞療法のための組成物および方法 |
CA3053252C (en) | 2017-03-08 | 2023-02-21 | Nantkwest, Inc. | Modified nk-92 hank003 cells for the clinic |
MX2019011324A (es) | 2017-03-23 | 2020-01-21 | Massachusetts Gen Hospital | Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano. |
US20200188433A1 (en) * | 2017-03-27 | 2020-06-18 | Nantcell, Inc. | aNK AND IL-12 COMPOSITIONS AND METHODS |
MX2019011514A (es) | 2017-03-27 | 2020-01-27 | Nat Univ Singapore | Receptores quimericos nkg2d truncados y usos de los mismos en inmunoterapia con celulas asesinas naturales. |
US11896616B2 (en) | 2017-03-27 | 2024-02-13 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
AU2018251898A1 (en) * | 2017-04-13 | 2019-10-31 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
WO2019028337A1 (en) | 2017-08-04 | 2019-02-07 | Nantkwest, Inc. | TREATMENT AND INHIBITION OF LEUKEMIA USING NK-92 CELLS |
US20200283501A1 (en) * | 2017-10-26 | 2020-09-10 | Regents Of The University Of Minnesota | Recombinant immune cells, methods of making, and methods of use |
WO2019084284A1 (en) | 2017-10-27 | 2019-05-02 | Coneksis, Inc. | NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS |
US20210187024A1 (en) | 2017-11-01 | 2021-06-24 | Nantkwest, Inc. | NK-92 Cells to Stimulate Anti-Cancer Vaccine |
JP2021512147A (ja) | 2018-01-22 | 2021-05-13 | エンドサイト・インコーポレイテッドEndocyte, Inc. | Car t細胞の使用方法 |
DE112019000608B4 (de) | 2018-01-31 | 2021-05-06 | Nantkwest, Inc. | Verwendung von 5 % humanalbumin in wasch- und erntemedien |
CN112004829A (zh) | 2018-03-12 | 2020-11-27 | 南克维斯特公司 | Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途 |
US20190321402A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
CA3099806A1 (en) * | 2018-05-14 | 2019-11-21 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
CA3098450A1 (en) | 2018-05-22 | 2019-11-28 | Nantkwest, Inc. | Basal media for growing nk-92 cells |
IL311918A (en) | 2018-05-22 | 2024-06-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
DK3797155T3 (da) * | 2018-05-22 | 2022-08-29 | Immunitybio Inc | Optimering af nk-92-cellevækst ved hjælp af poloxamer |
EP3797149A1 (de) | 2018-05-22 | 2021-03-31 | Nantkwest, Inc. | Verfahren und systeme zur zellbettbildung während der bioverarbeitung |
US20210267190A1 (en) | 2018-07-10 | 2021-09-02 | Nantkwest, Inc. | Cryopreservation |
IL296050A (en) | 2018-08-01 | 2022-10-01 | Immunitybio Inc | A quadricistronic system containing a receptor or cytokine and a chimeric antigen receptor for genetic modification of immunotherapies |
US20210293787A1 (en) | 2018-08-01 | 2021-09-23 | Nantkwest, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
EP3743512A4 (de) | 2018-10-31 | 2021-12-01 | Nantkwest, Inc. | Eliminierung von cd19-positiven lymphoidmalignitäten durch cd19-car-exprimierende nk-zellen |
JP7092404B2 (ja) | 2018-10-31 | 2022-06-28 | イミュニティーバイオ、インコーポレイテッド | Pd-l1キメラ抗原受容体を発現するnk細胞によるpd-l1陽性悪性腫瘍の排除 |
US11547727B2 (en) | 2018-11-06 | 2023-01-10 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
AU2019388876A1 (en) | 2018-11-26 | 2021-05-20 | Immunitybio, Inc. | IL-2 Dependent NK-92 cells with stable Fc receptor expression |
KR20210108409A (ko) * | 2018-12-20 | 2021-09-02 | 클레오 파마슈티컬스 인코포레이티드 | Arm과 자연 살해 세포의 조합 요법 |
CA3125503A1 (en) * | 2019-01-18 | 2020-07-23 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
WO2020188570A1 (en) * | 2019-03-19 | 2020-09-24 | Ramot At Tel-Aviv University Ltd. | T cell expressing an fc gamma receptor and methods of use thereof |
EP3712257A1 (de) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modifizierte natürliche killerzellen mit erhöhter resistenz gegen zelltod |
US20220143089A1 (en) | 2019-03-21 | 2022-05-12 | Onk Therapeutics Limited | Modified immune effector cells with increased resistance to cell death |
MX2021012967A (es) | 2019-04-23 | 2022-01-18 | Sanofi Sa | Anticuerpos y formulaciones de anti-cd38. |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
US20220144952A1 (en) * | 2019-08-01 | 2022-05-12 | Nantkwest, Inc. | Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells |
AU2020328050B2 (en) | 2019-08-15 | 2023-09-07 | Nantbio, Inc. | TGF-beta trap |
EP4061385A1 (de) * | 2019-11-19 | 2022-09-28 | Acibadem Mehmet Ali Aydinlar Üniversitesi | Verfahren zur neugestaltung und erweiterung von nk92-zellen zur verwendung in der immuntherapie |
GB2604813A (en) * | 2019-11-20 | 2022-09-14 | Immunitybio Inc | Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment |
EP3914699A4 (de) * | 2019-12-09 | 2023-03-29 | ImmunityBio, Inc. | Screening von zellklonen, die polygene transgene exprimieren, durch nichtantibiotische abhängige positive selektion |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
WO2021154218A1 (en) * | 2020-01-28 | 2021-08-05 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
CN113603787B (zh) * | 2020-05-04 | 2023-05-23 | 英诺康生物医药科技(广州)有限公司 | 一种非分泌型的人白细胞介素15及应用 |
EP4168438A4 (de) * | 2020-06-22 | 2024-07-10 | Univ Ramot | Proteinmodule mit mehreren untereinheiten, zellen zur expression davon und verwendungen davon |
TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
EP4108247A1 (de) | 2021-06-23 | 2022-12-28 | Ostravska univerzita | Harnvorläuferzellen zur verwendung in der krebstherapie |
WO2023081163A1 (en) | 2021-11-02 | 2023-05-11 | Immunitybio, Inc. | Natural killer cells for chordoma therapy |
EP4180049A1 (de) | 2021-11-16 | 2023-05-17 | Ostravska univerzita | Therapeutische zusammensetzung zur krebsbehandlung |
WO2023114901A2 (en) * | 2021-12-15 | 2023-06-22 | Oxford Biomedica Solutions Llc | Methods and compositions for the production of adeno-associated virus |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3733919A (en) * | 1971-09-20 | 1973-05-22 | Adjustable eccentric bearing mountings background | |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
ES2262163T3 (es) | 1988-05-27 | 2006-11-16 | Applied Research Systems Ars Holding N.V. | Receptor iii de fc gamma humano. |
US5767077A (en) | 1988-05-27 | 1998-06-16 | Applied Research Systems Ars Holding N.V. | Human Fc-γ receptor III |
EP0739904A1 (de) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispezifische Reagenzien für die AIDS-Therapie |
US7038031B1 (en) | 1989-07-28 | 2006-05-02 | Sloan-Kettering Institute For Cancer Research | DNA encoding FcγR receptor protein on NK cells |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0586505A1 (de) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heterokonjugat-antikörper zur behandlung von hiv-infektionen |
DK0758394T3 (da) | 1994-05-02 | 2003-03-03 | Bernd Groner | Bifunktionelt protein, fremstilling og anvendelse |
KR100343214B1 (ko) * | 1995-03-28 | 2002-11-13 | 삼성에스디아이 주식회사 | 전계방출소자의제조방법 |
US5830725A (en) | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
EP1007630B1 (de) | 1997-04-30 | 2006-04-19 | Hans Klingemann | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
US20030026780A1 (en) * | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
WO2003084570A1 (fr) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
US7618617B2 (en) * | 2002-05-31 | 2009-11-17 | L'oreal | Aqueous hair treatment compositions, thickened with an amphiphilic linear block copolymer |
MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
EP2287195B1 (de) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-rezeptor antikörper und deren diagnostische und therapeutische verwendung |
CA3052445C (en) * | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
PT1836225E (pt) | 2005-01-06 | 2012-01-10 | Novo Nordisk As | Agentes de ligação a kir e métodos de utilização dos mesmos |
-
2005
- 2005-07-08 CA CA3052445A patent/CA3052445C/en active Active
- 2005-07-08 ES ES18169049T patent/ES2925912T3/es active Active
- 2005-07-08 DK DK09164804T patent/DK2112162T3/da active
- 2005-07-08 WO PCT/US2005/024229 patent/WO2006023148A2/en active Application Filing
- 2005-07-08 CA CA2572938A patent/CA2572938C/en active Active
- 2005-07-08 DK DK14171739.7T patent/DK2801583T3/en active
- 2005-07-08 DK DK18169049.6T patent/DK3406631T3/da active
- 2005-07-08 US US11/178,258 patent/US7618817B2/en active Active
- 2005-07-08 EP EP15150984.1A patent/EP2921500B1/de active Active
- 2005-07-08 AT AT05789289T patent/ATE443084T1/de not_active IP Right Cessation
- 2005-07-08 DE DE200560016683 patent/DE602005016683D1/de active Active
- 2005-07-08 ES ES14171739.7T patent/ES2678094T3/es active Active
- 2005-07-08 PL PL15150984.1T patent/PL2921500T3/pl unknown
- 2005-07-08 ES ES15150984T patent/ES2955952T3/es active Active
- 2005-07-08 EP EP18169049.6A patent/EP3406631B1/de active Active
- 2005-07-08 EP EP20090164804 patent/EP2112162B1/de active Active
- 2005-07-08 AU AU2005277831A patent/AU2005277831B2/en active Active
- 2005-07-08 PT PT151509841T patent/PT2921500T/pt unknown
- 2005-07-08 EP EP14171739.7A patent/EP2801583B1/de active Active
- 2005-07-08 EP EP20050789289 patent/EP1771471B1/de not_active Revoked
- 2005-07-08 DK DK15150984.1T patent/DK2921500T3/da active
-
2008
- 2008-04-21 US US12/106,665 patent/US20080247990A1/en not_active Abandoned
-
2009
- 2009-09-22 US US12/564,255 patent/US9150636B2/en active Active
- 2009-09-22 US US12/564,283 patent/US8313943B2/en active Active
-
2012
- 2012-10-15 US US13/651,797 patent/US9181322B2/en active Active
-
2015
- 2015-05-11 HK HK15104418.9A patent/HK1203975A1/xx unknown
- 2015-08-26 US US14/836,927 patent/US20160067356A1/en not_active Abandoned
-
2016
- 2016-03-22 HK HK16103322.5A patent/HK1215269A1/zh unknown
-
2022
- 2022-10-27 US US18/050,216 patent/US20230372545A1/en active Pending
-
2023
- 2023-07-25 US US18/358,738 patent/US20240016957A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215269A1 (zh) | 基因修飾的人自然殺傷細胞系 | |
ECSP056117A (es) | Ligandos de receptores de cannabinoides y sus usos | |
WO2017201432A3 (en) | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity | |
IL186986A0 (en) | Compositions and methods for modulating immune responses | |
ATE475669T1 (de) | Einen modifizierten t-zellen-rezeptor exprimierende zellen | |
ATE373081T1 (de) | Zelllinie | |
ATE542920T1 (de) | Modifiziertes menschliches wachstumshormon | |
NO20091064L (no) | Antistoffer mot IL-17A | |
ATE546463T1 (de) | Modifizierte humane wachstumshormon-polypeptide und ihre verwendungen | |
WO2008033403A3 (en) | Agents and methods to elicit anti-tumor immune response | |
SG166090A1 (en) | Il-13 binding agents | |
LU91989I2 (fr) | Bydureon | |
GB0304068D0 (en) | Substances | |
BRPI0508629A (pt) | trilho lateral para uso com um suporte para paciente | |
DK1565183T3 (da) | Rapamycin og IL-10 til behandling af autoimmune sygdomme | |
TW200640482A (en) | Variant forms of urate oxidase and use thereof | |
WO2006029010A3 (en) | Methods of activating nkt cells | |
ATE409188T1 (de) | Naphthyridinverbindungen | |
EA200601894A1 (ru) | Производные пиперазинилпиперидина в качестве антагонистов хемокинового рецептора | |
GT200000200A (es) | Compuestos de 2,4-diamino-pirimidina utiles como supresores de inmunidad. | |
EA200801180A1 (ru) | Селективные пептидные агонисты рецептора vpac2 | |
ATE389670T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
GT200300199A (es) | Indoles 2,7-sustituidos | |
CA2466778A1 (en) | Flexible seat mount for chair seat bottom | |
DK1465927T3 (da) | BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |